Acute Agitation as a Behavioral Emergency:
Achieving Rapid Control and Maximizing Outcomes

 

CME INFORMATION

Needs Statement
This educational activity has been planned in accordance with the need to provide emergency physicians and emergency psychiatrists with the most current information on conventional and novel treatment options when treating the acutely agitated patient in an emergency room setting.


Educational Activity Objectives
At the conclusion of this course, participants should be able to:

  • Describe the challenges emergency department physicians face when treating the agitated patient;

  • Compare and contrast the various treatment options for acute agitation including conventional and new atypical antipsychotics;

  • Demonstrate the benefits of treatment choices for the emergency physician, the treatment team, and the patient.


Target Audience
The target audience for this activity is emergency physicians and emergency psychiatrists.


Accreditation Statement
This activity has been planned and produced in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME). The Center for Health Care Education, LLC, is accredited by the ACCME to provide continuing medical education for physicians.


Credit Statement
The Center for Health Care Education, LLC, (CHCE) designates this educational activity for a maximum of 1.75 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent on the educational activity. To receive credit please complete each presentation and fax or mail the Posttest Answer Sheet and Registration form to the CHCE.


Release/Expiration Statement
This activity is eligible for CME credit from July 2004 through July 30, 2005.


Commercial Support Acknowledgment
This activity is supported by an unrestricted educational grant from Pfizer Inc.


Disclosure of Off-Label Use of Medication
It is the policy of the CHCE, that faculty disclose to the attendees (1) when products/devices or procedures being discussed are off-label, unlabeled, experimental and/or investigational (not FDA approved); and (2) any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interm analyses, and/or unsupported opinion. Clinicians have the professional responsibility to ensure that drugs are prescribed and used appropriately based on their own clinical judgement and accepted standards of care. Please consult approved labeling for full prescribing information.


Faculty Disclosure of Commercial Interest
It is the policy of The Center for Health Care Education, LLC, to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty participating in a sponsored activity are expected to disclose to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of any commercial services included in the educational activity. The intent of this disclosure is not to prevent a faculty member with a significant financial or other relationship from participating in this activity, but rather to provide participants with information on which they can make their own judgments. It remains for the participants to determine whether the faculty member's interests or relationships may influence the content with regard to exposition or conclusion.


Faculty Type of Affiliation Commercial Entity

Douglas H. Hughes, MD    
  Consultant, Honorarium Janssen Pharmaceutica, Pfizer Inc.
  Stock Shareholder Johnson & Johnson, Merck & Co., Inc.

Dr. Hughes intends to discuss off-label/unapproved uses of products or devices in his presentation.


Lewis S. Nelson, MD, FACEP, FACMT

Dr. Nelson has no financial relationships to disclose.

Dr. Nelson intends to discuss off-label/unapproved uses of products or devices in his presentation.



Andrew Francis, MD, PhD
   
  Consultant Eli Lilly and Company, Janssen Pharmaceutica, Pfizer Inc.
  Honorarium

AstraZeneca Pharmaceuticals LP, Pfizer Inc.

Dr. Francis intends to discuss off-label/unapproved uses of products or devices in his presentation.


Grad Green, MSN, APRN, BC    

Consultant

Janssen Pharmaceutica, Pfizer Inc.

Ms. Green does not intend to discuss off-label/unapproved uses of products or devices in her presentation.


To view and/or print the Posttest Click Here

To receive CME credit, please complete the Activity Posttest Answer Sheet and Registration Form form and send to:

MAIL: Acute Agitation
            CHCE
            257 Route 80
            Killingworth, CT 06419

FAX:  860-663-5696


Privacy Policy

Information Collection and Use
A copy of the attendee list may be provided to the commercial supporter of this activity. You will have the option to not include your information on this list.

Contact Information
If there are any questions or concerns about our privacy policy, you may contact us at:
The Center for Health Care Education, LLC
257 Route 80
Killingworth, CT 06419
Phone: 800-260-4378
Fax: 860-663-5696
E-mail: info@chce.net

Copyright © 2003 by The Center for Health Care Education, LLC. All Rights Reserved.